Ivermectin and Human Immunity
Completed · Early Phase 1 · Has a placebo group
Conditions studied: Ivermectin
In brief
We hypothesize that ivermectin, a drug used to treat parasitic worm infections, interacts with the human innate immune system and that this contributes to its anti-parasitic effects. Participants will donate blood before and after being administered the normal human dose of the drug. We will compare the cell types present in the blood and the chemicals known to influence the human immune system before and after the drug is given, as well as measuring any changes in gene expression in white blood cells 4 and 24hrs after the drug is taken.
Key facts
- Study ID
- NCT03459794
- Run by
- University of Georgia
- People needed
- 12
- Starts
- 2018-02-12
- Expected to finish
- 2018-11-30
- Last updated by the study team
- 2019-07-12
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Weight over 110 pounds and under 185 pounds
You may not qualify if…
- Pregnancy or nursing mothers.
- Immunosuppressed individuals.
- Hypersensitivity to ivermectin, cellulose, starch, magnesium stearate, butylated hydroxyanisole, or citric acid powder (inert ingredients of Stromectol).
- Recent (last 3 years) travel to West or Central Africa, or any other country where onchocerciasis is present
- Hepatitis/HIV
- Currently taking warfarin
- Lactose intolerance (Lactose present in placebo)
- Currently taking Steroid medications (inhaled, oral or injection)
- Currently taking Barbiturates, Benzodiazepines such as Xanax or Klonopin, Valproic acid (Lithium), Calcium channel blockers, Statins (cholesterol medication)
- Liver or renal dysfunction
Where it is running
- University of Georgia — Athens, Georgia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.